CD30 expression in pediatric neoplasms, study of 585 cases

Pediatric and Developmental Pathology

Volumn 20, Issue 3, 2017, Pages 191-196

  Cheng, Jinjun ^a   Zhu, Haiqing ^b   Choi, John Kim ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CD30 expression; Immunohistochemistry; Oncology; Pediatric; Pediatric neoplasms; Tumors

Indexed keywords

CD30 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8;

ACUTE MYELOID LEUKEMIA; ANAPLASTIC LARGE CELL LYMPHOMA; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHATIC LEUKEMIA; BURKITT LYMPHOMA; CELL DIFFERENTIATION; CHILDHOOD CANCER; CHONDROBLASTOMA; CHRONIC MYELOID LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; EMBRYONAL CARCINOMA; GRANULOCYTIC SARCOMA; HEMANGIOMA; HEPATOSPLENIC DELTA T CELL LYMPHOMA; HEPATOSPLENIC GAMMA T CELL LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LANGERHANS CELL HISTIOCYTOSIS; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; NERVE CELL; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAINING; T CELL LYMPHOBLASTIC LEUKEMIA; T CELL LYMPHOBLASTIC LYMPHOMA; T CELL LYMPHOMA; TERATOMA; CHILD; METABOLISM; NEOPLASM;

CHILD; HUMANS; IMMUNOHISTOCHEMISTRY; KI-1 ANTIGEN; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 85027162957     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.1177/1093526616689185     Document Type: Article

References (13)

1. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196. doi:10.1200/JCO.2011.38.0402. PubMed PMID: 22614995.
2. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi:10.1200/JCO.2011.38.0410.
3. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385(9980):1853–62. doi:10.1016/S0140-6736(15)60165-9.
4. Dumaswala K, Mehta A. Novel agents for the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2015;8(5):659–667. doi:10.1586/17474086.2015.1081562.
5. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/ refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402. doi:10.1182/blood-2014-09-598763.
6. Alimchandani M, Wang ZF, Miettinen M. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases. Appl Immunohistochem Mol Morphol. 2014;22(5):358–362. doi:10.1097/PAI.0000000000 000048.
7. Polski JM, Janney CG. Ber-H2 (CD30) immunohistochemical staining in malignant melanoma. Mod Pathol. 1999;12(9): 903–906.
8. Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A. CD30 is a potential therapeutic target in malignant mesothelioma. Mol Cancer Therapeut. 2015;14(3):740–746. doi:10.1158/ 1535-7163.MCT-14-0972.
9. Giannatempo P, Paolini B, Miceli R, et al. Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. J Urol. 2013;190(5):1919–1924. doi: 10.1016/j.juro.2013.04.057.
10. Chittal SM, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin’s disease. The search for a rational panel. Am J Surg Pathol. 1988;12(1):9–21.
11. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–70. doi:10.1006/ smim.1998.0156.
12. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013; 121(14):2715–24. doi:10.1182/blood-2012-10-461848.
13. Wang XJ, Seegmiller AC, Reddy NM, Li S. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(1):39–47. doi:10.1111/ejh.12680.